KIR3DL1 and neoplasm: In summary, our evaluation of these immunogenotypes suggests that the repertoire of KIR/KIR-ligands that an individual inherits is associated with their clinical response to BEMPEG plus nivolumab therapy among those who are IO-naïve in the PIVOT-02 trial, which further supports a role for NK cells in the anti-tumor efficacy of this combination therapy.